Advertisement

Tumor Biology

, Volume 37, Issue 6, pp 7149–7154 | Cite as

Prognostic value of the neutrophil-to-lymphocyte ratio for overall and disease-free survival in patients with surgically treated esophageal squamous cell carcinoma

  • Joonho Jung
  • Seong Yong Park
  • Soo-jin Park
  • Jiye Park
Original Article

Abstract

Although increasing evidence indicates that cancers are associated with inflammation, the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) in patients with esophageal squamous cell carcinoma remains controversial. We determined the prognostic roles of NLR and PLR in patients with esophageal squamous cell carcinoma who underwent surgical treatment. We retrospectively reviewed 119 patients with esophageal squamous cell carcinoma who underwent surgical resection and complete lymph node dissection from 2004 to 2012. The preoperative NLR and PLR were measured. The patients included 112 (94.1 %) males (mean age, 63.64 ± 8.42 years) of whom 37 (31.1 %) were pathological stage I, 33 (27.7 %) were stage II, and 49 (41.2 %) were stage III. The median follow-up period was 28.68 months. Recurrence was reported in 48 (40.3 %) patients. Mean NLR and PLR were 2.35 ± 1.39 and 140.77 ± 70.47, respectively. A multivariate analysis revealed that NLR was a risk factor for disease-free survival (DFS) (hazard ratio [HR], 1.194; p = 0.031) and overall survival (OS) (HR, 1.230; p = 0.011), whereas PLR was not a risk factor for DFS or OS. The 3-year OS rates were 51.0 % in low-NLR (<2.97) patients and 17.4 % in high-NLR (≥2.97) patients (p = 0.007). Akaike’s information criterion decreased when the NLR was included in the multivariate model compared to the multivariate model without NLR. A high NLR was a significant prognostic factor for OS and DFS in patients with surgically treated esophageal squamous cell carcinoma, whereas PLR showed no prognostic significance.

Keywords

Esophageal cancer Neutrophil-to-lymphocyte ratio Statistics Survival analysis 

Notes

Compliance with ethical standards

The institutional review board of our institution approved this retrospective study (AJIRB-MED-MDB-15-400), and the requirement to obtain informed consent was waived.

Conflicts of interest

None

Funding sources

This study was supported by the new faculty research fund of Ajou University School of Medicine.

References

  1. 1.
    Garcia M, Jemal A, Ward E, Center M, Hao Y, Siegel R, et al. Global cancer facts and figures 2007. Atlanta, GA: American Cancer Society. 2007;1(3):52.Google Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Yuequan J, Shifeng C, Bing Z. Prognostic factors and family history for survival of esophageal squamous cell carcinoma patients after surgery. Ann Thorac Surg. 2010;90(3):908–13.CrossRefPubMedGoogle Scholar
  4. 4.
    Guo H, Zhu H, Xi Y, Zhang B, Li L, Huang Y, et al. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. J Nucl Med. 2007;48(8):1251–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Tachibana M, Hirahara N, Kinugasa S, Yoshimura H. Clinicopathologic features of superficial esophageal cancer: results of consecutive 100 patients. Ann Surg Oncol. 2008;15(1):104–16.CrossRefPubMedGoogle Scholar
  6. 6.
    Ancona E, Rampado S, Cassaro M, Battaglia G, Ruol A, Castoro C, et al. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol. 2008;15(11):3278–88.CrossRefPubMedGoogle Scholar
  7. 7.
    Lee PC, Port JL, Paul S, Stiles BM, Altorki NK. Predictors of long-term survival after resection of esophageal carcinoma with nonregional nodal metastases. Ann Thorac Surg. 2009;88(1):186–93.CrossRefPubMedGoogle Scholar
  8. 8.
    DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008;27(1):11–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.CrossRefPubMedGoogle Scholar
  10. 10.
    Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009;58(1):15–23.CrossRefPubMedGoogle Scholar
  11. 11.
    Ueno H, Hawrylowicz CM, Banchereau J. Immunological intervention in human diseases. J Transl Med. 2007;5(1):59.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Paramanathan A, Saxena A, Morris DL. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol. 2014;23(1):31–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Cedres S, Torrejon D, Martinez A, Martinez P, Navarro A, Zamora E, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012;14(11):864–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Proctor M, McMillan D, Morrison D, Fletcher C, Horgan P, Clarke S. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer. 2012;107(4):695–9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Rice TW, Blackstone EH, Rusch VW. of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17(7):1721–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Stylianou C, Pickles A, Roberts SA. Using Bonferroni, BIC and AIC to assess evidence for alternative biological pathways: covariate selection for the multilevel embryo-uterus model. BMC Med Res Methodol. 2013;13(1):73.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal. 2003;43(2):121–37.CrossRefGoogle Scholar
  18. 18.
    Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI, et al. Elevated preoperative neutrophil: lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol. 2011;18(12):3362–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sato H, Tsubosa Y, Kawano T. Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg. 2012;36(3):617–22.CrossRefPubMedGoogle Scholar
  20. 20.
    Rashid F, Waraich N, Bhatti I, Saha S, Khan RN, Ahmed J, et al. A pre-operative elevated neutrophil: lymphocyte ratio does not predict survival from oesophageal cancer resection. World J Surg Oncol. 2010;8(1):1–10.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Dutta S, Crumley AB, Fullarton GM, Horgan PG, McMillan DC. Comparison of the prognostic value of tumour-and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World J Surg. 2011;35(8):1861–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Feng J-F, Huang Y, Liu J-S. Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma. OncoTargets Ther. 2013;6:1605.Google Scholar
  23. 23.
    Feng J-F, Huang Y, Chen QX. A new inflammation index is useful for patients with esophageal squamous cell carcinoma. OncoTargets Ther. 2014;7:1811.CrossRefGoogle Scholar
  24. 24.
    Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey J-N. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. 2009;16(3):614–22.CrossRefPubMedGoogle Scholar
  25. 25.
    Aliustaoglu M, Bilici A, Ustaalioglu BBO, Konya V, Gucun M, Seker M, et al. The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol. 2010;27(4):1060–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Liao Q, Zhao Y-P, Yang Y-C, Li L-J, Long X, Han S-M. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int. 2007;6(6):641–5.PubMedGoogle Scholar
  27. 27.
    Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010;200(2):197–203.CrossRefPubMedGoogle Scholar
  28. 28.
    Klinger MH, Jelkmann W. Review: role of blood platelets in infection and inflammation. J Interf Cytokine Res. 2002;22(9):913–22.CrossRefGoogle Scholar
  29. 29.
    Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell. 2009;16(3):183–94.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005;365(9458):488–92.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Joonho Jung
    • 1
  • Seong Yong Park
    • 1
  • Soo-jin Park
    • 1
  • Jiye Park
    • 1
  1. 1.Department of Thoracic and Cardiovascular SurgeryAjou University School of MedicineSuwon-siSouth Korea

Personalised recommendations